Progenra
  • About
    • Investor Relations
    • Leadership
  • Covid-19 Therapeutics
  • Therapeutic Focus
    • The Ubiquitin Proteasome System (UPS)
    • UbiPro™ Platform
    • PROTAC Platform
    • Therapeutic Areas
  • Partnering
    • The Progenra Advantage
    • Partnering Opportunities
    • Collaborations
  • Careers
    • R&D, Biology
    • R&D, Medicinal Chemistry
  • News
    • News
    • Meetings
    • Publications
  • Blog
Select Page

Progenra Receives Second Immune Oncology Patent

by admin | May 12, 2017 | News

MALVERN, PA, May 10, 2017 –(BUSINESS WIRE) — Progenra, Inc. announced that it has received the Official Notice of Allowance (dated March 30, 2017) of its patent application entitled “Methods of treating cancer through the inhibition of USP7 and immune...

Recent Posts

  • Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.
  • Progenra Scientists publish a chapter in the ACS 2019 Medicinal Chemistry Reviews.
  • Characterization of Selective Covalent inhibitors of USP7- AACR Poster
  • Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
  • Immune Regulation by Protein Ubiquitination: Roles of the E3 Ligases VHL and Itch

Archives

  • May 2020
  • May 2019
  • December 2018
  • April 2018
  • March 2018
  • September 2017
  • June 2017
  • May 2017
  • December 2016
  • December 2015
Progenra Logo

Contact

  610.644.6974
  610.644.8616
   277 Great Valley Parkway
      Malvern PA, 19355

For More Information

  info@progenra.com
  bd@progenra.com
      (Business Development inquries)
  • Facebook
  • Twitter
  • LinkedIn
© 2021 Progenra Inc. All Rights Reserved.
Website Designed by eNet Web Services